The evolution of medulloblastoma therapy to personalized medicine [version 1; referees: 3 approved]

F1000Research

Scott Pomeroy¹  Soma Sengupta²  Daniel Pomeranz Krummel² 

[1] F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Boston, MA, USA;Winship Cancer Institute, Emory University Hospital, Atlanta, GA, USA;

关键词: Cancer Therapeutics;    Developmental & Pediatric Neurology;    Medical Genetics;    Neurobiology of Disease & Regeneration;    Neuro-Oncology;    Neuropharmacology & Psychopharmacology;    Pediatric Oncology;   

DOI  :  10.12688/f1000research.10859.1

来源: DOAJ

【 摘 要 】

Recent advances in cancer genomics have revolutionized the characterization and classification of medulloblastomas. According to the current WHO guidelines, medulloblastomas are now classified into the following molecularly defined groups: Wnt signaling pathway (WNT)-activated, sonic hedgehog signaling pathway (SHH)-activated and tumor suppressor protein p53 (TP53)-mutant, SHH-activated and TP53-wildtype, and non-WNT/non-SHH (i.e. group 3 and group 4). Importantly, genomic, epigenomic, and proteomic advances have created a potential paradigm shift in therapeutic options. The challenge now is to (i) translate these observations into new therapeutic approaches and (ii) employ these observations in clinical practice, utilizing the classification following a molecular analysis for diagnosis and application of new subgroup-specific targeted therapeutics.

【 授权许可】

Unknown